Crisaborole’s safety holds up in long-term atopic dermatitis trial

SCOTTSDALE, ARIZ. – The phosphodiesterase-4 inhibitor crisaborole was well tolerated over 6 to 12 months, yielding no major safety signals during a multicenter, open-label extension study of patients...
Source: Pediatric News - Category: Journals (General) Source Type: news